News
-
-
-
-
PRESS RELEASE
APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned
APONTIS PHARMA reports significant sales and earnings increase in 2024 financial year, plans squeeze-out and merger with Zentiva AG. EBITDA rises to EUR 3.5 million from previous year's EUR -13.3 million -
PRESS RELEASE
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Jaguar Health, Inc. reports a 20% increase in total net revenue for 2024, reaching $11.7 million. Expecting first results in Q2 2025 for crofelemer trials. FDA meeting scheduled for Phase 3 OnTarget trial -
-
PRESS RELEASE
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Tharimmune received positive feedback from the FDA on the 505(b)(2) NDA submission for TH104 buccal film for opioid prophylaxis. Company progressing CMC plan for NDA requirements -
-
-